Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/115367
Title: The consequences of the new European reclassification of non-invasive brain stimulation devices and the medical device regulations pose an existential threat to research and treatment: an invited opinion paper
Authors: Antal, Andrea
Ganho-Ávila, Ana
Assecondi, Sara
Barbour, Traci
Bjekić, Bjekić
Blumberger, Daniel M.
Bolognini, Nadia
Brunelin, Jerome
Chanes, Lorena
Dale, Mathew
Dubbioso, Raffaele
D'Urso, Giordano
Filipcic, Igor
Filipović, Saša R.
Hirnstein, Marco
Konings, Femke
Langguth, Berthold
Leocani, Letizia
Memarian Sorkhabi, Majid
Mulder, Mark
Nikander, Mika
Nowak, Rafal
Oliviero, Antonio
Onarheim, Balder
O'Shea, Jacinta
Pallanti, Stefano
Rachid, Fady
Rajão-Saraiva, Joana
Rossi, Simone
Sack, Alexander T.
Sauvaget, Anne
van der Scheer, Rik
Schellhorn, Klaus
Soria-Frisch, Aureli
Szekely, David
Tankisi, Hatice
Taylor, Paul CJ.
Tendolkar, Indira
Baeken, Chris
Issue Date: Apr-2024
Publisher: Elsevier
Project: UID/PSI/01662/2013 
Serial title, monograph or event: Clinical Neurophysiology
Abstract: A significant amount of European basic and clinical neuroscience research includes the use of transcranial magnetic stimulation (TMS) and low intensity transcranial electrical stimulation (tES), including transcranial direct current stimulation (tDCS). Two recent changes in the EU regulations, the introduction of the Medical Device Regulation (MDR) (2017/745) and the Annex XVI have caused significant problems and confusions in the brain stimulation field. The negative consequences of the MDR for non-invasive brain stimulation (NIBS) have been largely overlooked and until today, have not been consequently addressed by National Competent Authorities, local ethical committees, politicians and by the scientific communities. In addition, a rushed bureaucratic decision led to seemingly wrong classification of NIBS products without an intended medical purpose into the same risk group III as invasive stimulators. Overregulation is detrimental for any research and for future developments, therefore researchers, clinicians, industry, patient representatives and an ethicist were invited to contribute to this document with the aim of starting a constructive dialogue and enacting positive changes in the regulatory environment.
URI: https://hdl.handle.net/10316/115367
DOI: https://doi.org/10.1016/j.clinph.2024.03.039
Rights: embargoedAccess
Appears in Collections:FPCEUC - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat Login
Antal et al 2024_Final_Accepted_22_03_24.pdf674.42 kBAdobe PDFEmbargo Access    Request a copy
Show full item record

Page view(s)

118
checked on Oct 9, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons